Antiretroviral-drug resistance among patients recently infected with HIV

New England Journal of Medicine

Volumn 347, Issue 6, 2002, Pages 385-394

  Little, Susan J ^a,o   Holte, Sarah ^b   Routy, Jean Pierre ^c   Daar, Eric S ^d   Markowitz, Marty ^f   Collier, Ann C ^a,k   Koup, Richard A ^d,e   Mellors, John W ^g,k,l   Connick, Elizabeth ^h,k   Conway, Brian ^m   Kilby, Michael ⁿ   Wang, Lei ^o   Whitcomb, Jeannette M ^i,j   Hellmann, Nicholas S ⁿ   Richman, Douglas D ^a,k,m  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^f HARBOR UCLA MEDICAL CENTER   (United States)

^g AARON DIAMOND AIDS RESEARCH CENTER   (United States)

^h NATIONAL INSTITUTES OF HEALTH   (United States)

ⁱ UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^j UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^k UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^l University of Alabama at Birmingham   (United States)

^m MONOGRAM BIOSCIENCES   (United States)

ⁿ VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^o UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; STAVUDINE; ZALCITABINE;

ADOLESCENT; ADULT; ARTICLE; DIAGNOSTIC TEST; DRUG SENSITIVITY; EVALUATION; FEMALE; FREQUENCY ANALYSIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; IC 50; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; NORTH AMERICA; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SEQUENCE ANALYSIS; TREATMENT FAILURE; TREATMENT INDICATION; VIRUS MUTATION;

EID: 0037043652     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa013552     Document Type: Article

References (49)

1. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
2. Altered natural history of AIDS-related opportunistic infections in the era of potent combination antiretroviral therapy
3. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease
4. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease
5. Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: Results of AIDS Clinical Trials Group protocol 315
6. Impact of drug resistance mutations on virologic response to salvage therapy: Swiss HIV Cohort Study
7. Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy
8. HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed
9. New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes
10. Reduced antiretroviral drug susceptibility among patients with primary HIV infection
11. HIV-1 drug resistance in newly infected individuals
12. Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society-USA Panel
13. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1
14. Antiretroviral drug resistance testing in adult HIV-1 infection: Recommendations of an International AIDS Society-USA Panel
15. Increase in the frequency of mutation at codon 215 associated with zidovudine resistance in HIV-1-infected antiviral-naive patients from 1989 to 1996
16. Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons
17. Primary infection with zidovudine-resistant human immunodeficiency virus type 1
18. Heterosexual transmission of human immunodeficiency virus type 1 variants associated with zidovudine resistance
19. R-) HIV-1 in Switzerland, Australia, and the United States between 1988 and 1994
20. Mutations associated with zidovudine resistance in HIV-1 among recent seroconvertors
21. Primary lamivudine resistance in acute/early human immunodeficiency virus infection
22. First case of new infection with zidovudine-resistant HIV-1 among prospectively studied intravenous drug users and homosexual men in Amsterdam, the Netherlands
23. Transmission of zidovudine-resistant human immunodeficiency virus type 1 variants following deliberate injection of blood from a patient with AIDS: Characteristics and natural history of the virus
24. Transmission from one child to another of human immunodeficiency virus type 1 with a zidovudine-resistance mutation
25. Occurrence of HIV-1 reverse transcriptase gene mutation at codon 215 in HIV-infected infants
26. Vertical transmission of multidrug-resistant human immunodeficiency virus type 1 (HIV-1) and continued evolution of drug resistance in an HIV-1-infected infant
27. Selective vertical transmission of HIV-1 antiretroviral resistance mutations
28. Zidovudine genotypic resistance in HIV-1-infected newborns in the French perinatal cohort
29. Transmission of human immunodeficiency virus type 1 resistant to nevirapine and zidovudine
30. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors
31. Transmission of antiretroviral-drug-resistant HIV-1 variants
32. Drug resistance patterns, genetic subtypes, clinical features, and risk factors in military personnel with HIV-1 seroconversion
33. Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use
34. Acute HIV infection: Impact on the spread of HIV and transmission of drug resistance
35. Prevalence of transmitted nucleoside analogue-resistant HIV-1 strains and pre-existing mutations in pol reverse transcriptase and protease region: Outcome after treatment in recently infected individuals
36. Analysis of prevalence of HIV-1 drug resistance in primary infections in the United Kingdom
37. Reduced susceptibility of human immunodeficiency virus type 1 (HIV-1) from patients with primary HIV infection to nonnucleoside reverse transcriptase inhibitors is associated with variation at novel amino acid sites
38. The care of HIV-infected adults in the United States
39. The prevalence of antiretroviral drug resistance in the US
40. HIV incidence among young men who have sex with men - Seven U.S. cities, 1994-2000
41. Outbreak of syphilis among men who have sex with men - Southern California, 2000
42. Increases in unsafe sex and rectal gonorrhea among men who have sex with men - San Francisco, California, 1994-1997
43. Recent increases in HIV seroconversion among repeat anonymous testers in San Francisco
44. Antiretroviral resistance and response to initial therapy among recently HIV-infected subjects in North America
45. Persistence of transmitted drug resistance among subjects with primary HIV infection not receiving antiretroviral therapy
46. Recovery of replicationcompetent HIV despite prolonged suppression of plasma viremia
47. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy
48. Will transmission of drug resistant HIV be driven by individuals infected with drug resistant strains?